

Step Therapy Edit Criteria Proposal



Drug/Drug Class: **Retinoic Acid Products/Retinoid Analogues - Topical**
 Date: **June 22, 2005**
 Prepared for:
 Prepared by: **Missouri Medicaid**

☐ **New Criteria**

☒ **Revision of Existing Criteria**

Executive Summary

Purpose: To monitor and control pharmacy expenditures by removing the retinoic acid products from Prior Authorization, and incorporating them into a clinical edit, step therapy with the retinoid analogues.

Why was this Issue Selected: For the previous fiscal year, the Missouri Medicaid Pharmacy Program paid approximately \$250,000 for retinoid analog products. Conversely, approximately \$50,000 was spent on retinoic acid product claims. Now that the retinoic acid products are available generically, there will be favorable program impact by reducing product restriction.

	Drug	AWP	Claims
Program-specific information:	• Tazorac 0.1% Gel	\$2.84	355
	• Differin 0.1% Gel	\$2.19	2,027
	• Retin-A Micro 0.05% Cr	\$2.32	108
	• Retin-A 0.025% Gel	\$1.93	96
	• Tretinoin 0.025% Gel	\$1.72	55

Setting & Population: All patients over the age of 21 years.

Type of Criteria: ☐ **Increased risk of ADE** ☐ **Non-Preferred Agent**
☒ **Appropriate Indications** ☐

Data Sources: ☒ **Only administrative databases** ☐ **Databases + Prescriber-supplied**

Purpose of Clinical Edit Criteria

Under the Omnibus Budget Reconciliation Act of 1993, Congress intended Prior Authorization or Prior Approval (PA) programs to control utilization of products that have very narrow indications or high abuse potential. While prescription expenditures are increasing at double-digit rates, payors are also evaluating ways to control these costs by influencing prescriber behavior and guide appropriate medication usage. Clinical edit criteria assist in the achievement of qualitative and economic goals related to health care resource utilization. Restricting the use of certain medications can reduce costs by requiring documentation of appropriate indications for use, and where appropriate, encourage the use of less expensive agents within a drug class. Clinical Edit criteria can also reduce the risk for adverse events associated with medications by identifying patients at increased risk due to diseases or medical conditions, or those in need of dosing modifications.

Setting & Population

- Drug class for review: Retinoic Acid Products/Retinoid Analogues
- Age range: All patients over the age of 21 years.
- Diagnosis: NA

Approval Criteria

Reference Drug Products: Retinoic Acid Products

- Approved Diagnoses

Condition	Submitted ICD-9 Diagnoses	Inferred Drugs	Date Range
Skin Cancer	172 – 173 176.0 232	---	730 days
Lamellar Ichtyosis	757.1	---	730 days
Darier's Disease	757.39	---	730 days
Acne Vulgaris	706.1	---	730 days
Drug Induced Acne	692.3	---	730 days

- Trial and failure on covered benzyl peroxide product (required for acne diagnoses only)



Retinoid Analogue Products :

- Appropriate Diagnosis
 - Acne
 - **Psoriasis (Tazorac only)**
 - No required trial and failure on benzyl peroxide product
 - No required trial and failure on retinoic acid product

Condition	Submitted ICD-9 Diagnoses	Inferred Drugs	Date Range
Acne	706.1	---	730 days
Drug Induced Acne	692.3	---	730 days
Psoriasis (Tazorac Only)	696.0 –696.8	---	730 days

- Trial and failure on retinoic acid product
- Documented ADE/ADR to retinoic acid product
- Documented lack of acne control/ineffective response on retinoic acid product

Denial Criteria

Retinoic Acid Products:

- Inappropriate Diagnosis/Cosmetic Uses
- Lack of trial and failure on benzyl peroxide products

Retinoid Analogue Products:

- Inappropriate Diagnosis/Cosmetic Uses
- Lack of trial and failure on retinoic acid products

Required Documentation

Laboratory results:

☐
☐

MedWatch form:

Progress notes:

☐
☐

Other:

Disposition of Edit

- **Denial:** Edit 681 “Step Therapy Edit”

References

1. USPDI, Micromedex, 2005.
2. Facts and Comparisons®, p.1687-1698, 2005.
3. American Family Physician. “Management of Acne Vulgaris.” July 1994.
4. Journal of American Academy of Dermatology. “Topical Tretinoin in Acne Therapy.” August 1998.
5. Allergan, Inc., Irvine CA. “Tazorac Information – Psoriasis, Place in Therapy.” December 2004.

